
Latest updates
Our experts keep on top of the markets to bring you the latest on what's shaking up stock prices.
11 January 2023: Johnson & Johnson’s consumer health unit Kenvue has filed for IPO. The unit has filed to be listed as an independent company under the ticker symbol KVUE. Goldman Sachs and J.P. Morgan are the underwriters for the offering. Upon completion of the IPO, J&J will retain ownership of at least 80.1% of the voting power of shares of common stock.
Johnson & Johnson (JNJ) is a publicly traded drug manufacturers-general business based in the US. It opened the day at $161.69 after a previous close of $162. During the day the price has varied from a low of $161.07 to a high of $163.43. The latest price was $163.42 (25 minute delay). Johnson & Johnson is listed on the NYSE. All prices are listed in US Dollars.
How to buy shares in Johnson & Johnson
- Choose a platform. If you're a beginner, our share-dealing table below can help you choose.
- Open your account. You'll need your ID, bank details and national insurance number.
- Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
- Search the platform for stock code: JNJ in this case.
- Research Johnson & Johnson shares. The platform should provide the latest information available.
- Buy your Johnson & Johnson shares. It's that simple.
What's in this guide?
- Can I buy shares in Johnson & Johnson?
- Compare share dealing platforms
- Performance over time
- Is Johnson & Johnson stock a buy or sell?
- Are Johnson & Johnson shares over-valued?
- Is Johnson & Johnson suitable for ethical investing?
- Johnson & Johnson shares summary
- Does Johnson & Johnson pay a dividend?
- How volatile are Johnson & Johnson shares?
- Other common questions
Fees for buying 5x Johnson & Johnson shares with popular platforms
Both exchange rates and share prices fluctuate in real time, so the costs presented here should be considered as a guide only. They do not incorporate stamp duty. Always refer to the platform itself for availability and pricing – which may differ from our information.
Platform | Platform fee | Min. initial deposit | Trading fee estimate | |
---|---|---|---|---|
![]() |
£0 | $50 | £3.32 £666.80 total |
Capital at risk |
![]() |
£0 | £250 | £11.48 £674.96 total |
Capital at risk |
![]() |
£0 | £1 | £2.99 £666.47 total |
Capital at risk |
![]() |
£0 | No minimum | £6.63 £670.12 total |
Capital at risk |
![]() |
£0 | £1 | £18.58 £682.07 total |
Capital at risk |
![]() |
£0 | £0.01 | £0.66 £664.15 total |
Capital at risk |
![]() |
£9.99 per month | No minimum | £17.94 £681.43 total |
Capital at risk |
![]() |
£36 per year | £20 | £17.79 £681.28 total |
Capital at risk |
![]() |
£0 | £50 | £3.32 £666.80 total |
Capital at risk |
Full comparison of share dealing platforms
Johnson & Johnson share price (NYSE:JNJ)
Use our graph to track the performance of JNJ stocks over time.Johnson & Johnson price performance over time
Historical closes compared with the last close of $163.42
1 week (2023-01-25) | -3.59% |
---|---|
1 month (2022-12-30) | -7.49% |
3 months (2022-11-01) | -5.59% |
6 months (2022-08-01) | -6.03% |
1 year (2022-02-01) | -4.37% |
---|---|
2 years (2021-02-01) | 0.44% |
3 years (2020-01-31) | 9.77% |
5 years (2018-01-31) | 18.26% |
Is it a good time to buy Johnson & Johnson stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page.
Invest in Johnson & Johnson shares with 0% commission
- Start investing from $50
- Pay no stamp duty on UK shares
- Join 30 million users who trust their investments with eToro
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
Is Johnson & Johnson under- or over-valued?
Valuing a stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of overall performance. However, analysts commonly use some key metrics to help gauge value.
P/E ratio
Johnson & Johnson's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 25x. In other words, Johnson & Johnson shares trade at around 25x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
However, Johnson & Johnson's P/E ratio is best considered in relation to those of others within the drug manufacturers-general industry or those of similar companies.
- Pfizer (PFE.US): 8.57
- Gilead Sciences (GILD.US): 31.83
- Abbott Laboratories (ABT.US): 25.40
- IDEXX Laboratories (IDXX.US): 60.99
- GSK (GSK.LSE): 12.72
- AstraZeneca (AZN.LSE): 103.98
PEG ratio
Johnson & Johnson's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 3.7929. Higher PEG ratios such as this can be interpreted as meaning the shares offer worse value given the current rate of growth.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Johnson & Johnson's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
However, it's sensible to consider Johnson & Johnson's PEG ratio in relation to those of similar companies.
- Pfizer (PFE.US): 1.17
- Gilead Sciences (GILD.US): 0.72
- Abbott Laboratories (ABT.US): 18.76
- IDEXX Laboratories (IDXX.US): 7.21
- GSK (GSK.LSE): 1.11
- AstraZeneca (AZN.LSE): 1.37
EBITDA
Johnson & Johnson's EBITDA (earnings before interest, taxes, depreciation and amortisation) is a whopping $32.6 billion (£26.5 billion).
The EBITDA is a measure of a Johnson & Johnson's overall financial performance and is widely used to measure a its profitability.
To put that into context you can compare it against similar companies.
- Pfizer (PFE.US): USD$44.8 billion
- Gilead Sciences (GILD.US): USD$12.8 billion
- Abbott Laboratories (ABT.US): USD$13.7 billion
- IDEXX Laboratories (IDXX.US): USD$982.3 million
- GSK (GSK.LSE): £11.7 billion
- AstraZeneca (AZN.LSE): £13.6 billion
Environmental, social and governance track record
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Johnson & Johnson.
Total ESG risk score
Johnson & Johnson's total ESG risk: 35.8
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Johnson & Johnson's overall score of 35.8 (as at 01/01/2019) is pretty weak – landing it in it in the 72nd percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Johnson & Johnson is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
To gain some more context, you can compare Johnson & Johnson's total ESG risk score against those of similar companies.
- Pfizer (PFE.US): 33.15
- Gilead Sciences (GILD.US): 22.15
- Abbott Laboratories (ABT.US): 32.35
- IDEXX Laboratories (IDXX.US): 29.79
- GSK (GSK.LSE): 28.51
- AstraZeneca (AZN.LSE): 28.52
Environmental score
Johnson & Johnson's environmental score: 3.79/100
Johnson & Johnson's environmental score of 3.79 puts it squarely in the 7th percentile of companies rated in the same sector. This could suggest that Johnson & Johnson is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score
Johnson & Johnson's social score: 25.14/100
Johnson & Johnson's social score of 25.14 puts it squarely in the 7th percentile of companies rated in the same sector. This could suggest that Johnson & Johnson is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score
Johnson & Johnson's governance score: 14.87/100
Johnson & Johnson's governance score puts it squarely in the 7th percentile of companies rated in the same sector. That could suggest that Johnson & Johnson is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score
Johnson & Johnson's controversy score: 4/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. A high-profile company, Johnson & Johnson scored a 4 out of 5 for controversy – the second-lowest score possible, reflecting that Johnson & Johnson has a damaged public profile.
Wondering how that compares? Below are the controversy scores of similar companies.
- Pfizer (PFE.US): 3
- Gilead Sciences (GILD.US): 2
- Abbott Laboratories (ABT.US): 3
- GSK (GSK.LSE): 3
- AstraZeneca (AZN.LSE): 3
Environmental, social, and governance (ESG) summary
Johnson & Johnson was last rated for ESG on: 2019-01-01.
Total ESG score | 35.8 |
---|---|
Total ESG percentile | 72.38 |
Environmental score | 3.79 |
Environmental score percentile | 7 |
Social score | 25.14 |
Social score percentile | 7 |
Governance score | 14.87 |
Governance score percentile | 7 |
Level of controversy | 4 |
Johnson & Johnson shares at a glance
Open | $161.69 |
---|---|
High | $163.43 |
Low | $161.07 |
Close | $163.42 |
Previous close | $162 |
Change | $1.42 |
Change % | 0.8765% |
Volume | 11,500,784 |
52-week range | $152.7074 - $183.0782 |
---|---|
50-day moving average | $175.653 |
200-day moving average | $173.2376 |
Wall St. target price | $183.58 |
PE ratio | 25.1872 |
Dividend yield | $4.45 (2.69%) |
Earnings per share (TTM) | $6.73 |
Johnson & Johnson share dividends
Dividend yield: 2.69% of stock value
Forward annual dividend yield: 2.69% of stock value
Dividend payout ratio: 36.78% of net profits
Johnson & Johnson has recently paid out dividends equivalent to 2.69% of its share value annually.
Johnson & Johnson has paid out, on average, around 36.78% of recent net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 2.69% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), shareholders could enjoy a 2.69% return on their shares, in the form of dividend payments. In Johnson & Johnson's case, that would currently equate to about $4.45 per share.
While Johnson & Johnson's payout ratio might seem fairly standard, it's worth remembering that it may be investing much of the rest of its net profits in future growth.
Johnson & Johnson's most recent dividend payout was on 7 March 2023. The latest dividend was paid out to all shareholders who bought their shares by 17 February 2023 (the "ex-dividend date").
Johnson & Johnson's dividend yield is perhaps best considered in relation to those of similar companies.
- Pfizer (PFE.US): 3.65% (3.65% forward annual dividend yield)
- Gilead Sciences (GILD.US): 3.51% (3.51% forward annual dividend yield)
- Abbott Laboratories (ABT.US): 1.79% (1.79% forward annual dividend yield)
- IDEXX Laboratories (IDXX.US): 0.00% (does not pay dividend)
- GSK (GSK.LSE): 5.40% (5.4% forward annual dividend yield)
- AstraZeneca (AZN.LSE): 1.98% (1.98% forward annual dividend yield)
Share price volatility
Over the last 12 months, Johnson & Johnson's shares have ranged in value from as little as $152.7074 up to $183.0782. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Johnson & Johnson's is 0.5706. This would suggest that Johnson & Johnson's shares are less volatile than average (for this exchange).
To put Johnson & Johnson's beta into context you can compare it against those of similar companies.
- Pfizer (PFE.US): 0.6331
- Gilead Sciences (GILD.US): 0.4262
- Abbott Laboratories (ABT.US): 0.6676
- IDEXX Laboratories (IDXX.US): 1.1441
- GSK (GSK.LSE): 0.2918
- AstraZeneca (AZN.LSE): 0.231
Shares similar to Johnson & Johnson
Johnson & Johnson in the news
Sony Scales Back PlayStation VR2 Output, Sam Bankman-Fried Attempted To Regain Control Of FTX, White House Plans To End COVID-19 Emergency: Today's Top Stories
10 Best February Dividend Stocks To Buy
J&J’s Court Loss Weakens Controversial Legal Tactic Used by Big Companies
Frequently asked questions
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
More guides on Finder
-
How to buy Blue Water Vaccines (BWV) shares in the UK
Ever wondered how to buy shares in Blue Water Vaccines? We explain how and compare a range of providers that can give you access to many brands, including Blue Water Vaccines.
-
How to buy Veru (VERU) shares in the UK
Ever wondered how to buy shares in Veru? We explain how and compare a range of providers that can give you access to many brands, including Veru.
-
How to buy C4 Therapeutics (CCCC) shares in the UK
Ever wondered how to buy shares in C4 Therapeutics? We explain how and compare a range of providers that can give you access to many brands, including C4 Therapeutics.
-
How to buy Clever Leaves (CLVR) shares in the UK
Ever wondered how to buy shares in Clever Leaves? We explain how and compare a range of providers that can give you access to many brands, including Clever Leaves.
-
How to buy NeuroSense Therapeutics (NRSN) shares in the UK
Ever wondered how to buy shares in NeuroSense Therapeutics? We explain how and compare a range of providers that can give you access to many brands, including NeuroSense Therapeutics.
-
Mental health stocks: Popular mental health companies to invest in
Mental health stocks can be rewarding, but there are risks involved that could impact your profits. Find out how to invest in companies in the mental health industry.
-
Invest in pharmaceutical stocks
Pharma stocks can be rewarding, but there are risks involved that could impact your profits. Find out the best way to invest in pharma stock.
-
How to buy Bone Biologics (BBLG) shares in the UK
Ever wondered how to buy shares in Bone Biologics? We explain how and compare a range of providers that can give you access to many brands, including Bone Biologics.
-
How to buy Adagio Therapeutics (ADGI) shares in the UK
Ever wondered how to buy shares in Adagio Therapeutics? We explain how and compare a range of providers that can give you access to many brands, including Adagio.
-
How to buy Bolt Biotherapeutics (BOLT) shares in the UK
Ever wondered how to buy shares in Bolt Biotherapeutics? We explain how and compare a range of providers that can give you access to many brands, including Bolt Biotherapeutics.
Ask an Expert